MBC is stage IV or advanced breast cancer which gets metastasized from the breast organ to the lymph nodes (armpit area) or may be anywhere in the body. Lung, liver, bone, and brain are the common metastatic sites of the breast cancer. After the surgical removal, very minute tumor cells...
ERα, microRNAs, and the epithelial–mesenchymal transition in breast cancer The most common form of breast cancer, luminal A, is estrogen receptor α (ERα)-positive and epithelial, but nevertheless can metastasize. The process of epithelial–mesenchymal transition (EMT) is probably the first step...
Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial CDK4/6 inhibition is often effective for those with breast cancer but success is limited by adverse reacti...
F-FDG glucose analog distribution provided further evidence that the first metastatic sites of distant tumor progression are PTNs. Tumor invasion caused disruptions in the tissue of the primary renal tumor, releasing cancer cells into the peritoneal cavity. Colloidal particles, among them bacteria and ...
and dissociate from the initial site, intravasation, survival in the blood or lymphatic circulation, extravasation, and ultimately colonize distant sites. Exosomes from BC cells are crucial orchestrators to condition the pre-metastatic niche microenvironment in metastatic progression. Breast cancer BC, ep...
Invasive ductal carcinoma: This cancer starts in the milk ducts of the breast and grows into other parts of the surrounding tissue. It is the most common form of breast cancer. About 80% of invasive breast cancers are invasive ductal carcinoma. ...
By definition, metastatic breast cancer (MBC) is not curable. If you have stage 4 breast cancer it means that it's spread far beyond the breast and nearby tissue; it's likely infiltrated the brain, bones, liver, or lungs. "There's a misconception that breast cancer always gets cured,...
The FDA and Eagle Pharmaceuticals have agreed on the next steps for the development of EA-114, an estrogen receptor antagonist and novel formulation of fulvestrant used in the treatment of postmenopausal women with breast cancer.
Subclone composition can vary over space (within the same tumor mass or across metastatic sites) and time (sequential samples). All subclones in a cancer are by definition genetically related, having arisen from a single common ancestor, but individual subclones are distinguished by the existence ...
[3]Yongmei Yin, et al. Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study.2025 ASCO. Abstract #1019. ...